Biotech Values

[DewDiligence]

EXAS +11% on 1Q15 results:

http://finance.yahoo.com/news/exact-sciences-reports-strong-growth-090000965.html
http://www.thestreet.com/story/13136925/1/exact-sciences-exas-stock-gains-on-earnings-beat.html

Exact Sciences reported a loss of 40 cents a share for the first quarter, above analysts' estimates of a loss of 41 cents a share. The company reported revenue of $4.3 million for the first quarter, compared to analysts' estimates of $4.1 million.

The company said that 11,000 Cologuard tests were completed in the first quarter. The number of ordering physicians grew to 8,300 in the first quarter, up from 4,100 in the year-ago quarter.

I can’t get my own doctor to even acknowledge that Cologuard exists; the practice still uses FIT and insists that it’s the SoC.